ViCentra announced today that it appointed former Dexcom and Medtronic Diabetes leaders to new executive roles. The Dutch insulin pump maker continues to expand its senior leadership as it looks to advance its Kaleido patch pump system. It appointed Karen Baxter, former VP and GM at Dexcom, to the position of SVP of sales for […]
Business/Financial News
Dexcom adds Stanford Medicine chair to its board of directors
Dexcom (Nasdaq:DXCM) announced today that it appointed Dr. Euan Ashley to its board of directors, effective Oct. 24, 2025. Ashley, a renowned researcher, entrepreneur and clinician, brings extensive leadership experience across healthcare research institutions and private organizations. He currently serves as chair of the Dept. of Medicine at Stanford Health. Research areas for Ashley span […]
Vivani prices $15.7M offering
Vivani Medical (Nasdaq:VANI) announced that it priced a best efforts registered direct offering of 6 million shares of common stock. The Alameda, California-based company priced the shares at $1.62 apiece. It also announced a concurrent private placement of more than 3.7 million shares of common stock at the same price. Gregg Williams, the company’s board […]
Ypsomed launches YpsoLoop autoinjector platform designed for circularity
Ypsomed announced that it launched YpsoLoop, its first autoinjector platform designed for circularity. The Swiss drug delivery device maker says the two new 1 mL and 2.25 mL platforms enable material recovery. Their design enables automated disassembly and efficient recycling while offering the convenience of a pre-filled, two-step autoinjector. Ypsomed said the YpsoLoop platform integrates […]
Insulet adds JPMorgan veteran to its board of directors
Insulet (Nasdaq:PODD) announced today that it appointed Robert “Robbie” L. Huffines to its board of directors. Huffines, a former global chair of investment banking at JPMorgan Chase & Co., joins the automated insulin delivery technology maker’s board effective Oct. 31, 2025. He joins as an independent director and a member of the Insulet Audit Committee. […]
Abbott makes Lingo OTC CGM available for sale at Walmart
Abbott (NYSE:ABT) today shared that it made its Lingo biowearable device available for purchase at Walmart stores. This marks the first availability for the over-the-counter continuous glucose monitor (CGM) at a brick-and-mortar retailer. It brings the Lingo device to more than 3,500 Walmart Supercenter locations (in their health and wellness sections) in the U.S. and […]
Dexcom is facing a class action suit related to G7 CGM
A class action lawsuit has been filed against Dexcom (Nasdaq:DXCM) in the U.S. District Court for the Central District of California. The lawsuit, led by plaintiff Kelly Grisoli on behalf of all others similarly situated, demands a jury trial for claims that Dexcom’s representations for its latest-generation G7 continuous glucose monitor (CGM) were false, misleading, […]
Baxter faces investor lawsuit over infusion pumps
Investors have filed a lawsuit claiming Baxter (NYSE:BAX) violated federal securities laws as a result of issues with certain infusion pumps. Bloomberg Law first reported the filing of the lawsuit in Illinois. The class action suit seeks a trial by jury as investors hope to recover damages related to the rollout of its Novum IQ […]
Civica to launch affordable long-acting insulin in pre-filled pens in 2026
Civica announced today that it plans to launch an affordable long-acting insulin in pre-filled pens starting in January 2026. The company plans to launch insulin glargine-yfgn in pre-filled pens at the lowest list price in the current long-acting insulin market. It intends to make the offering available in the U.S. beginning on Jan. 1, 2026. […]
Abbott CEO expects continued growth in Diabetes Care with Libre 3, dual sensor
Abbott (NYSE:ABT) continues to get a boost in its Medical Devices business from its Diabetes Care unit’s portfolio of continuous glucose monitors (CGMs). In the company’s third-quarter earnings report released today, Abbott — one of the largest medtech companies in the world — fell shy of Wall Street’s sales expectations, but still reported more than 15% […]
